Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 4.5% – Here’s What Happened

Posted by Brenda Bartman on Aug 30th, 2026

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report)’s share price dropped 4.5% on Friday . The company traded as low as $0.3150 and last traded at $0.3150. 115 shares were traded during mid-day trading, a decline of 100% from the average session volume of 31,817 shares. The stock had previously closed at $0.33.

Anebulo Pharmaceuticals Trading Down 4.5%

The firm’s 50-day moving average price is $0.33 and its 200-day moving average price is $0.47. The stock has a market capitalization of $12.85 million, a PE ratio of -1.66 and a beta of -1.82.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 28.40% of the company’s stock.

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.